My research interests are focused on developing novel methods for detecting, monitoring, and treating hematologic malignancies; particularly non-Hodgkin lymphomas (NHLs). I aim to create tools to rapidly detect and quantify tumors and their response to chemotherapy and immunotherapy, thereby enabling personalized therapies. Toward this end, I utilize tools from a wide range of disciplines, including bioengineering, computational biology, and medical oncology. I previously implemented high-throughput sequencing of the immunoglobulin genes from plasma cell-free DNA for detection of diffuse large B cell and follicular lymphomas (DLBCL and FL), the two most common types of lymphoma. This work demonstrated the superior efficacy of this assay from cell-free DNA as compared to circulating white blood cells, and has led to its translation to the clinic. Recently, I have implemented targeted next-generation sequencing for ultra-sensitive detection of circulating tumor DNA utilizing Cancer Personalized Profiling by Deep Sequencing, or CAPP-Seq, for use in NHLs. This work has led to a number of important applications in the field, including early detection of disease relapse, non-invasive genotyping of tumors, and detection of transformation of follicular lymphoma into DLBCL.